Market Cap
€127.5m
Last Updated
2020/05/29 22:21 UTC
Data Sources
Company Financials +
Executive Summary
Medigene AG, a clinical stage immuno-oncology company, focuses on the development of T cell immunotherapies for the treatment of cancer.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet and fair value.
Share Price & News
How has Medigene's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MDG1's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
3.2%
MDG1
1.7%
DE Biotechs
4.3%
DE Market
1 Year Return
-31.1%
MDG1
9.3%
DE Biotechs
0.3%
DE Market
Return vs Industry: MDG1 underperformed the German Biotechs industry which returned 9.3% over the past year.
Return vs Market: MDG1 underperformed the German Market which returned 0.3% over the past year.
Shareholder returns
| MDG1 | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.2% | 1.7% | 4.3% |
| 30 Day | 18.4% | 18.5% | 7.4% |
| 90 Day | 20.3% | 15.3% | -0.2% |
| 1 Year | -31.1%-31.1% | 9.6%9.3% | 2.0%0.3% |
| 3 Year | -56.0%-56.0% | 17.7%16.1% | -5.0%-12.3% |
| 5 Year | -42.0%-42.0% | 19.1%16.9% | 4.2%-9.2% |
Price Volatility Vs. Market
How volatile is Medigene's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
News Flash: Analysts Just Made A Huge Upgrade To Their Medigene AG (ETR:MDG1) Forecasts2 months ago | Simply Wall St
How Should Investors Feel About Medigene AG's (ETR:MDG1) CEO Pay?3 months ago | Simply Wall St
If You Had Bought Medigene (ETR:MDG1) Stock Three Years Ago, You'd Be Sitting On A 64% Loss, TodayValuation
Is Medigene undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MDG1 (€5.19) is trading below our estimate of fair value (€31.23)
Significantly Below Fair Value: MDG1 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MDG1 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: MDG1 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MDG1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MDG1 is good value based on its PB Ratio (1.6x) compared to the DE Biotechs industry average (5.2x).
Next Steps
Future Growth
How is Medigene forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
37.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDG1 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MDG1 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MDG1 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MDG1's revenue (37.6% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: MDG1's revenue (37.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MDG1 is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Medigene performed over the past 5 years?
-22.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MDG1 is currently unprofitable.
Growing Profit Margin: MDG1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MDG1 is unprofitable, and losses have increased over the past 5 years at a rate of -22.9% per year.
Accelerating Growth: Unable to compare MDG1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDG1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).
Return on Equity
High ROE: MDG1 has a negative Return on Equity (-24.4%), as it is currently unprofitable.
Next Steps
Financial Health
How is Medigene's financial position?
Financial Position Analysis
Short Term Liabilities: MDG1's short term assets (€57.7M) exceed its short term liabilities (€10.2M).
Long Term Liabilities: MDG1's short term assets (€57.7M) exceed its long term liabilities (€17.2M).
Debt to Equity History and Analysis
Debt Level: MDG1 is debt free.
Reducing Debt: MDG1 has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MDG1 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: MDG1 has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 5.7% each year.
Next Steps
Dividend
What is Medigene's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MDG1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MDG1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MDG1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MDG1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MDG1's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.1yrs
Average management tenure
CEO
Dolores Schendel
4.25yrs
Tenure
€487,000
Compensation
Prof. Dr. Dolores J. Schendel has been the Chief Executive Officer and Member of Executive Management Board at MediGene AG since February 1, 2016 and May 1, 2014 respectively. Prof. Dr. has been the Chief ...
CEO Compensation Analysis
Compensation vs Market: Dolores's total compensation ($USD538.42K) is about average for companies of similar size in the German market ($USD417.67K).
Compensation vs Earnings: Dolores's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chief Scientific Officer & Member of Executive Management Board | 4.25yrs | €487.00k | no data | |
| Co-Founder & Member of the Supervisory Board | 7.33yrs | €33.00k | 0.16% €203.1k | |
| CFO, Chief Business Development Officer & Member of Executive Management Board | 1.08yrs | €687.93k | no data | |
| Chief Medical Officer | 2.08yrs | €457.00k | no data | |
| Co-Founder & Chairman Scientific Advisory Board | 2.75yrs | €20.00k | no data | |
| Vice President of Investor Relations | 0.58yr | no data | no data |
2.1yrs
Average Tenure
Experienced Management: MDG1's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Member of the Supervisory Board | 7.33yrs | €33.00k | 0.16% €203.1k | |
| Co-Founder & Chairman Scientific Advisory Board | 2.75yrs | €20.00k | no data | |
| Member of Supervisory Board | 3yrs | €23.00k | no data | |
| Deputy Chairwomen of the Supervisory Board | 3.75yrs | €35.00k | no data | |
| Chairman of the Supervisory Board | 1yr | €39.00k | no data | |
| Member of Supervisory Board | 3yrs | €27.00k | no data | |
| Member of the Supervisory Board | 2yrs | €27.00k | 0.082% €104.8k | |
| Member of Scientific Advisory Board | 2.75yrs | no data | no data | |
| Member of the Supervisory Board | 6.83yrs | €26.00k | no data | |
| Member of Scientific Advisory Board | 2.75yrs | no data | no data |
2.9yrs
Average Tenure
61yo
Average Age
Experienced Board: MDG1's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Medigene AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Medigene AG
- Ticker: MDG1
- Exchange: XTRA
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €127.480m
- Shares outstanding: 24.56m
- Website: https://www.medigene.com
Number of Employees
Location
- Medigene AG
- Lochhamer Strasse 11
- Planegg/Martinsried
- Munich
- Bavaria
- 82152
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MDG1 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2000 |
| MDG1 | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Jun 2000 |
| 0QGJ | LSE (London Stock Exchange) | Yes | Common Stock | GB | EUR | Jun 2000 |
| MDGE.F | OTCPK (Pink Sheets LLC) | Yes | Common Stock | US | USD | Jun 2000 |
| MDG1D | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Common Stock | GB | EUR | Jun 2000 |
| MDG1 | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | Jun 2000 |
| MDG1 | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Jun 2000 |
| MDG1 | ETLX (Eurotlx) | Yes | Common Stock | IT | EUR | Jun 2000 |
Biography
Medigene AG, a clinical stage immuno-oncology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company operates in two segments, Immunotherapies and Other products. It is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells and associated projects, which are in pre-clinical and clinical development. It also focuses on DC vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal and Institute for Research in Immunology and Cancer — Commercialization of Research, Canada; and with Cytovant Sciences Co. Ltd. and PHIO Pharmaceuticals Corp. It has operations in Europe, the United States, Greater China, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/05/29 22:21 |
| End of Day Share Price | 2020/05/29 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.